When the Trump administration in September debuted TrumpRx.gov as part of its deal with Pfizer at “most favored nation” prices, my mind immediately turned to

Metsera has now received new takeover bids from both Pfizer and Novo Nordisk, and has plumped for a sweetened $10bn offer from the latter.

Plus, news about Kaigene, Celltrion, Solid Bio, Terns Pharmaceuticals, Benitec, Pacira, AmacaThera, UCB, Basilea Pharmaceutica, Pfizer, Kura Oncology, Kyowa Kirin, Novavax, Sanofi, Syndexis and Relmada:

Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in

Hours before a pivotal court hearing, Novo Nordisk has increased its offer for obesity biotech Metsera to as much as $10 billion, trying to outdo